Kim G G, Donnenberg V S, Donnenberg A D, Gooding W, Whiteside T L
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
J Immunol Methods. 2007 Aug 31;325(1-2):51-66. doi: 10.1016/j.jim.2007.05.013. Epub 2007 Jun 28.
Natural killer (NK) cell-or T cell-mediated cytotoxicity traditionally is measured in 4-16 h (51)Cr-release assays (CRA). A new four-color flow cytometry-based cytotoxicity assay (FCC) was developed to simultaneously measure NK cell cytotoxicity and NK cell phenotype (CD3(-)CD16(+)CD56(+)). Target cells, K562 or Daudi, were labeled with Cell Tracker Orange (CTO) prior to the addition of effector cells. Following co-incubation, 7 amino-actinomycin D (7-AAD) was added to measure death of target cells. The phenotype of effectors, viability of targets, the formation of tumor-effector cell conjugates and absolute numbers of all cells were measured based on light scatter (FSC/SSC), double discrimination of the fluorescence peak integral and height, and fluorescence intensity. Kinetic studies (0.5 and 1 to 4 h) at different effector to target (E:T) cell ratios (50, 25, 12, and 6) confirmed that the 3 h incubation was optimal. The FCC assay is more sensitive than the CRA, has a coefficient of variation (CV) 8-13% and reliably measures NK cell-or lymphokine-activated killer (LAK) cell-mediated killing of target cells in normal controls and subjects with cancer. The FCC assay can be used to study a range of phenotypic attributes, in addition to lytic activity of various subsets of effector cells, without radioactive tracers and thus, it is relatively inexpensive. The FCC assay has a potential for providing information about molecular interactions underlying target cell lysis and thus becoming a major tool for studies of disease pathogenesis as well as development of novel immune therapies.
J Immunol Methods. 2001-7-1
J Immunol Methods. 2005-10-30
Curr Protoc Immunol. 2012-4
J Clin Immunol. 2025-5-24
Cell Transplant. 2024
Cytotherapy. 2024-2
J Immunol Methods. 2006-6-30
Annu Rev Immunol. 2006
J Invest Dermatol. 2006-1
Methods Mol Biol. 2004
Exp Cell Res. 2003-10-1